Tech Company Financing Transactions
LinusBio Funding Round
Private investors invested in a $8 million Series A funding round for LinusBio. The financing round was announced on 5/31/2023.
Transaction Overview
Company Name
Announced On
5/31/2023
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series A
Investors
Proceeds Purpose
LinusBio plans to leverage the funding to extend international partnerships and scale up production of its early autism diagnostic aid test - StrandDx�ASD - in a newly opened facility in North Brunswick, New Jersey.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
101 6th Ave,
New York, NY 10013
USA
New York, NY 10013
USA
Phone
Undisclosed
Website
Email Address
Overview
LinusBio is a patient-centric, precision exposome medicine company headquartered in New York, NY. Originating from the world's leading exposome laboratory at Mount Sinai Health System, Linus has developed a technology platform that builds on breakthroughs in exposome sequencing by trailblazing researchers Drs. Manish Arora, Christine Austin and Paul Curtin.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Manish Arora
Chief Financial Officer
Kathy Ryan
Chief Operating Officer
Ronak Kadakia
Co-Founder
Christine Austin
Co-Founder
Paul Curtin
Browse more venture capital transactions:
Prev: 5/31/2023: Violet Therapeutics venture capital transaction
Next: 5/31/2023: Cloudsky Technologies venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs